OR-OREGON-SYMPHONY
9.2.2021 19:17:04 CET | Business Wire | Press release
The Oregon Symphony is proud to announce that acclaimed Austrian-born conductor David Danzmayr will serve as its next Music Director with the launch of its 2021-2022 season and the symphony’s 125th anniversary year. Regarded as one of today’s most gifted conductors, Danzmayr recently served as Chief Conductor of the Zagreb Philharmonic Orchestra and Music Director of ProMusica Chamber Orchestra. He has conducted orchestras at some of the world's most prominent concert halls in Germany, Italy, Scotland and major cities across the United States. Danzmayr follows esteemed Music Director Carlos Kalmar , who has held the position with the Oregon Symphony for the last 18 years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210209005045/en/
“We are thrilled to have David joining the Oregon Symphony as a creative leader with a unique artistic vision,” shares Scott Showalter, Oregon Symphony President and CEO. “His inaugural season, with the implementation of his Creative Alliance, reflects his desire to embrace wide-ranging cultures while inspiring and challenging audiences, and is sure to open another rich chapter in Oregon Symphony history.”
Danzmayr holds a strong belief that a composer’s musical expression is shaped by their personal environment, family heritage and culture, which will be reflected in the Symphony’s 2021-2022 season programming and launch of the Oregon Symphony Creative Alliance. Danzmayr’s vision unites a wide-range of musical innovators to create vibrant work from unique perspectives. Under Danzmayr, the Creative Alliance will feature extraordinary artists and cultural thought leaders, including Nathalie Joachim, Gabriela Lena Frank, Jun Märkl, Gabriel Kahane, Simone Lamsma and Johannes Moser.
“The Oregon Symphony is one of the county's top orchestras, with talented musicians and a passionate community, and I am honored to have been selected as its next Music Director,” says Danzmayr.” As part of my agenda, I’m committed to building upon the Symphony's high standard of excellence with music that is meaningful to Oregon audiences.”
Danzmayr will join the four-time Grammy-nominated Oregon Symphony for its pivotal 125th anniversary, marking a profound milestone as the Symphony continues its legacy as the oldest orchestra in the Western United States.
"Oregon is proud to share 125 years with our beloved Oregon Symphony, and I want to personally welcome David Danzmayr as its new Music Director,” says Gov. Kate Brown. “The Oregon Symphony is one of our state’s artistic treasures, and the last 18 years with Carlos Kalmar as Music Director have been phenomenal. I can't wait to see what the symphony achieves under David’s leadership."
The Oregon Symphony will announce its 2021-2022 season in March 2021. For information about David Danzmayr, visit www.orsymphony.org/Danzmayr .
About Oregon Symphony
Led by Music Director Carlos Kalmar, the Oregon Symphony serves more than 235,000 people annually through concerts and award-winning education and community programs. The Symphony continues to innovate through series such as SoundSights, Sounds of Home and SoundStories. Follow the Oregon Symphony on Instagram and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005045/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom